May 21 (Reuters) - Antisense Therapeutics Ltd ANP.AX :
* PHASE II CLINICAL TRIAL OF ATL1102 FOR DUCHENNE MUSCULAR DYSTROPHY MET PRIMARY ENDPOINT
* ANTISENSE ATL1102 FINAL PHASE II DMD RESULTS EXCEED EXPECTATIONS ON SECONDARY ENDPOINTS
May 21 (Reuters) - Antisense Therapeutics Ltd ANP.AX :
* PHASE II CLINICAL TRIAL OF ATL1102 FOR DUCHENNE MUSCULAR DYSTROPHY MET PRIMARY ENDPOINT
* ANTISENSE ATL1102 FINAL PHASE II DMD RESULTS EXCEED EXPECTATIONS ON SECONDARY ENDPOINTS